Overall survival benefit with pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer in CLEOPATRA, a randomised Phase 3 study

BACKGROUND: Primary results from the randomised, double-blind phase 3 study CLEOPATRA demonstrated significantly improved median progression-free survival (PFS) with pertuzumab plus trastuzumab plus docetaxel versus placebo plus trastuzumab plus docetaxel in patients with human epidermal growth fact...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Swain, Sandra M., Kim, Sung-Bae, Cortés, Javier, Ro, Jungsil, Semiglazov, Vladimir, Campone, Mario, Ciruelos, Eva, Ferrero, Jean-Marc, Schneeweiss, Andreas, Knott, Adam, Clark, Emma, Ross, Graham, Benyunes, Mark C., Baselga, José
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4076842/
https://ncbi.nlm.nih.gov/pubmed/23602601
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(13)70130-X
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados